Date: 30th. May 2013
Barcelona, May 27th, 2013. Sanofi , one of the world’s leading pharmaceutical companies has joined Biocat's Design Health Barcelona program as Corporate Partner. The company, with a strong commitment to innovation to improve patients’ quality of life will actively cooperate with Biocat’s talent incubator to promote entrepreneurship in hospitals.
"We are very proud that a company such as Sanofi has decided to join us and to help boost both Catalan health and life sciences ecosystems through innovation" says Montserrat Vendrell, CEO of Biocat. "We hope this will be the first of a series of supporting initiatives to the program. We are negotiating with other companies interested in d•HEALTH and also with banks to offer financial facilities to the fellows."
Carme Miquel, Director of Strategy, Business Development and Business Support at Sanofi, said that "in Sanofi we are committed to seek strategic alliances with external partners that add value. We feel proud about joining Biocat via its Design Health Barcelona program because it is a highly strategic partner for us. Innovation is a key pillar in all the areas of our organization and we believe that this project will push us to be even more pioneers in the search for new solutions that provide value to patients. At the end, patients are at the heart of all our activities."
d·HEALTH Barcelona is a pioneering training initiative to boost innovation in which real needs identified at hospital settings will become the basis of new technologies to improve the quality medical care. Inspired by the prestigious Stanford Biodesign Fellowship and FutureMed (Singularity University) programs, d·HEALTH Barcelona is the flagship program of Moebio, Biocat’s new initiative to develop the entrepreneurial talent in both healthcare and life sciences sectors.
d·HEALTH Barcelona is aimed at postgraduates in medicine, biosciences, engineering, economics and design who want to make a change in their careers and pursue entrepreneurship in the health sector. During eight months, selected fellows will work in multidisciplinary teams of four. The process will start with an immersion at a clinical setting in Barcelona to identify real unmet, needs. Then, fellows will design and prototype new products and services to solve them and, at the end of the program, they will pitch their innovations to a panel of investors to get the funding to implement them. Throughout the process, fellows will receive an intensive introduction to the clinical field to become experts on the chosen specialty area, will learn how to build a viable business and will receive training in areas such as design thinking or creative leadership through a series of classes and workshops taught by over 50 international experts.
d·HEALTH Barcelona program’s international collaborators include KaosPilots, the prestigious Danish school of new business design and social innovation. Christer Windeløv-Lidzélius, the CEO of the KaosPilots, is a member of the program’s Advisory Board and will teach students how to become creative leaders. Moebio has an Advisory Board which includes, among others, the aforementioned Christer Windeløv-Lidzélius, Anurag Mairal, Global Exhange Programs Director (Stanford), Lluís Torner, director of ICFO, John Collins (CIMIT), Yossi Bahagon (Health Services), Menno Van Dijk (THNK, The Amsterdam School of Creative Leadership); Neo Kok-Beng (Stanford Biodesign, Singapore) and Xavier Verdaguer (Imagine).
In the coming weeks, Biocat will participate and will explain the characteristics of the biodesign innovation process and of d·HEALTH Barcelona program at Biz Barcelona, Barcelona Design Week and MIHealth Forum among other public events.
Nota: If you are interested in attending these events or contacting any of the experts listed in this press release, please call Biocat’s press office.
Biocat is the organization that coordinates and promotes the biotechnology, biomedicine and medical technology sector in Catalonia. Created in 2006 thanks to the Government of Catalonia and the Barcelona City Council, Biocat brings together administrations, universities, research centers, companies and support bodies from all areas of the biomedicine and biotechnology sector with a major goal: to create an environment with a strong research system, active transfer of knowledge and an entrepreneurial business fabric that acts as a driving force for the country's economy and contributes to the wellbeing of society as a whole. www.biocat.cat
Sanofi, is a global diversified leader in the healthcare industry. It discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has seven growth platforms in healthcare: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY) stock markets.
FOR MORE INFORMATION
Press Office • email@example.com
Zuberoa Marcos • 686 575 178
Mònica López • 657 985 544
You can also follow us in:
Blog, Twitter, Facebook i LinkedIn
Press Office: ES-Comunicacion@sanofi.com
Alex Pérez: firstname.lastname@example.org (607 662 651)
10th. April 2018
Electronic glasses, low-cost exoesqueletons and wearables improving stress resilience, among projects selected for acceleration program CRAASH Barcelona
14th. February 2018
Biocat and experts from Boston help bring European healthcare research to market with CRAASH Barcelona program
29th. May 2017
d·HEALTH Barcelona consolidates place among top European health-acceleration programs driving disruptive entrepreneurship
3rd. June 2016
d·HEALTH Barcelona start-ups focus on medical devices for fecal incontinence, breastfeeding and constipation
The University of Barcelona masters degree promoted by Biocat trains entrepreneurs for the health sector following the biodesign method created at Stanford
19th. May 2015
Training future health entrepreneurs at Barcelona hospitals following Stanford model
d·HEALTH Barcelona seeks graduates or PhDs in engineering, design, business administration or life sciences for upcoming edition